Medicine Man Technologies Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Medicine Man Technologies's earnings have been declining at an average annual rate of -30.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 45.1% per year.
Belangrijke informatie
-30.5%
Groei van de winst
-8.0%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 45.1% |
| Rendement op eigen vermogen | -65.7% |
| Nettomarge | -38.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Medicine Man Technologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 175 | -68 | 79 | 0 |
| 31 Mar 24 | 174 | -61 | 75 | 0 |
| 31 Dec 23 | 172 | -43 | 71 | 0 |
| 30 Sep 23 | 169 | -41 | 70 | 0 |
| 30 Jun 23 | 166 | -39 | 69 | 0 |
| 31 Mar 23 | 168 | 2 | 66 | 0 |
| 31 Dec 22 | 159 | -26 | 59 | 0 |
| 30 Sep 22 | 146 | 9 | 52 | 0 |
| 30 Jun 22 | 134 | 10 | 52 | 0 |
| 31 Mar 22 | 121 | -18 | 46 | 0 |
| 31 Dec 21 | 108 | 7 | 39 | 0 |
| 30 Sep 21 | 90 | -7 | 40 | 0 |
| 30 Jun 21 | 65 | -11 | 35 | 0 |
| 31 Mar 21 | 40 | -22 | 33 | 0 |
| 31 Dec 20 | 24 | -19 | 30 | 0 |
| 30 Sep 20 | 19 | -14 | 27 | 0 |
| 30 Jun 20 | 15 | -13 | 24 | 0 |
| 31 Mar 20 | 12 | -15 | 20 | 0 |
| 31 Dec 19 | 11 | -17 | 17 | 0 |
| 30 Sep 19 | 9 | -18 | 11 | 0 |
| 30 Jun 19 | 9 | -11 | 9 | 0 |
| 31 Mar 19 | 9 | -2 | 6 | 0 |
| 31 Dec 18 | 8 | 1 | 5 | 0 |
| 30 Sep 18 | 7 | 5 | 5 | 0 |
| 30 Jun 18 | 5 | -1 | 4 | 0 |
| 31 Mar 18 | 4 | -5 | 8 | 0 |
| 31 Dec 17 | 3 | -5 | 7 | 0 |
| 30 Sep 17 | 2 | -6 | 7 | 0 |
| 30 Jun 17 | 2 | -6 | 6 | 0 |
| 31 Mar 17 | 1 | -1 | 1 | 0 |
| 31 Dec 16 | 1 | -1 | 1 | 0 |
| 30 Sep 16 | 1 | 0 | 1 | 0 |
| 30 Jun 16 | 1 | 0 | 1 | 0 |
| 31 Mar 16 | 1 | 0 | 1 | 0 |
| 31 Dec 15 | 1 | 0 | 1 | 0 |
| 30 Sep 15 | 1 | 0 | 1 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: SHWZ is currently unprofitable.
Groeiende winstmarge: SHWZ is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SHWZ is unprofitable, and losses have increased over the past 5 years at a rate of 30.5% per year.
Versnelling van de groei: Unable to compare SHWZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SHWZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: SHWZ has a negative Return on Equity (-65.73%), as it is currently unprofitable.